SNNのチャート
SNNの企業情報
| symbol | SNN |
|---|---|
| 会社名 | Smith_Nephew Plc （スミス・アンド・ネフュ―） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | スミス・アンド・ネフュー(Smith_Nephew plc)は整形外科用再建と外傷、内視鏡検査（スポーツ医学と呼ばれる関節鏡処置を含む）及び先進創傷管理の市場で事業を運営するグローバルな医療機器会社。同社は整形外科事業、内視鏡検査事業、及び先進創傷管理事業という３つの事業セグメントを運営する。同社は世界的な規模で事業を展開し、90カ国以上にて販売・流通経路を有する。整形外科再建インプラントは股関節、膝関節と肩関節、及びセメント関節再建手術に使用される骨セメントとミキシングシステムなど補助的な製品を含む。内視鏡検査事業は外科医向けに軟部組織と連接型関節の治療・修復のための内視鏡（低侵襲手術）技術、教育プログラムとサービスの開発・商品化を行う。先進創傷管理事業は初期創面環境調整から完全な創傷閉鎖まで一連の製品を提供する。平成23年6月23日、同社はTenet Medical Engineering Inc.を買収した。 スミス・アンド・ネフュ―はイギリスの医療機器メ―カ―。主要製品はウンドマネジメント、エンドスコピ―、オ―ソペディックスの3種に大別される。ウンドマネジメント製品には、絆創膏や創傷治癒システムがある。オ―ソペディックス製品は、人工関節や創外固定器などを含む。エンドスコピ―製品には、関節鏡視下手術用の医療機器がある。本社はロンドン。 Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. |
| 本社所在地 | 15 Adam Street London WC2N 6LA GBR |
| 代表者氏名 | Namal Nawana |
| 代表者役職名 | Chief Executive Officer Executive Director |
| 電話番号 | +44 20-7401-7646 |
| 設立年月日 | 1937年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 16681人 |
| url | www.smith-nephew.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 1432.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 17312.45000 |
| 売上高 | （百万ドル） 4904.00000 |
| 企業価値(EV) | （百万ドル） 18412.45000 |
| 当期純利益 | （百万ドル） 663.00000 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Smith_Nephew plc (ADR) revenues increased 3% to $4.9B. Net income before extraordinary items decreased 17% to $663M. Revenues reflect United States of America segment increase of 1% to $2.35B. Net income was offset by Restructuring_Rationalisation Costs increase from $0K to $120M (expense) Legal and Other increase from $16M (income) to $21M (expense). |
SNNのテクニカル分析
SNNのニュース
Citi maintains Smith & Nephew at ''buy'' with a price target of GBP14.00 2023/05/31 08:04:35 Investing.com
https://www.investing.com/news/pro/smith-and-nephew-receives-investment-bank-analyst-rating-update-3094565
Berenberg maintains Smith & Nephew at ''buy'' with a price target of GBP15.00 2023/05/17 06:03:35 Investing.com
https://www.investing.com/news/pro/smith-and-nephew-receives-investment-bank-analyst-rating-update-3084319
Smith & Nephew: Need Strong Rotation Of Capital Into Market Value For FY23 2023/05/14 05:05:59 Seeking Alpha
Smith & Nephew has caught a 21% bid the past 6 months, despite no major fundamental changes. Click here to read why SNN stock is a Hold.
Regenerative Medicine Market Report Size, Research Analysis, Share, Industry Growth, Opportunities, Business Expansion, Forecast to 2027 2023/05/10 13:00:00 SBWire
In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function. Northbrook, IL 60062 -- ( SBWIRE ) -- 05/10/2023 -- The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to grow at a CAGR of 27.2% from 2022 to 2027. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and issues associated with commercialization and regulatory compliance factors are expected to restrain the market growth during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579 Regenerative Medicine Industry Dynamics Drivers: Availability of funding and rising investments in R&D The rising need for improved therapies for cancer, diabetes, skin diseases, musculoskeletal diseases, chronic wounds, burns, and CVD has resulted in increased research activities.
Bernstein maintains Smith & Nephew at ''outperform'' with a price target of GBP15.80 2023/05/09 05:47:49 Investing.com
https://www.investing.com/news/pro/smith-and-nephew-receives-investment-bank-analyst-rating-update-3076624
Citi maintains Smith & Nephew at ''buy'' with a price target of GBP14.00 2023/05/31 08:04:35 Investing.com
https://www.investing.com/news/pro/smith-and-nephew-receives-investment-bank-analyst-rating-update-3094565
Berenberg maintains Smith & Nephew at ''buy'' with a price target of GBP15.00 2023/05/17 06:03:35 Investing.com
https://www.investing.com/news/pro/smith-and-nephew-receives-investment-bank-analyst-rating-update-3084319
Smith & Nephew: Need Strong Rotation Of Capital Into Market Value For FY23 2023/05/14 05:05:59 Seeking Alpha
Smith & Nephew has caught a 21% bid the past 6 months, despite no major fundamental changes. Click here to read why SNN stock is a Hold.
Regenerative Medicine Market Report Size, Research Analysis, Share, Industry Growth, Opportunities, Business Expansion, Forecast to 2027 2023/05/10 13:00:00 SBWire
In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function. Northbrook, IL 60062 -- ( SBWIRE ) -- 05/10/2023 -- The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to grow at a CAGR of 27.2% from 2022 to 2027. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and issues associated with commercialization and regulatory compliance factors are expected to restrain the market growth during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579 Regenerative Medicine Industry Dynamics Drivers: Availability of funding and rising investments in R&D The rising need for improved therapies for cancer, diabetes, skin diseases, musculoskeletal diseases, chronic wounds, burns, and CVD has resulted in increased research activities.
Bernstein maintains Smith & Nephew at ''outperform'' with a price target of GBP15.80 2023/05/09 05:47:49 Investing.com
https://www.investing.com/news/pro/smith-and-nephew-receives-investment-bank-analyst-rating-update-3076624
Prolocor Announces Appointment of Edward L. Rosen to Its Board of Directors 2023/03/09 14:00:00 Accesswire
PHILADELPHIA, PA / ACCESSWIRE / March 9, 2023 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa on the surface of platelets, today announced that Edward L. Rosen has joined the company''s Board of Directors. Rosen is a highly accomplished and well-respected industry expert and has held numerous senior-level positions during his illustrious career. Prolocor Logo Prolocor Logo Most recently, Rosen served as Chief Strategy & Commercial Officer at Clinical Genomics, where he generated and implemented an integrated commercial strategy, delivered successful IP licensing, and oversaw efforts that gained Medicare and Medicare Advantage reimbursement coverage. Prior to joining Clinical Genomics, he served as Executive-in-Residence at Columbia University (Office of Technology Ventures), where he collaborated with entrepreneurs and inventors to facilitate the transfer of research innovations from the lab to the market, as well as supporting start-up efforts across therapeutic, diagnostic and device applications.
Smith & Nephew plc: Smith+Nephew''s VISIONAIRE Patient-Specific Instrumentation shown to improve outcome measures for total knee arthroplasty compared with conventional instrumentation 2023/03/06 13:06:00 Finanz Nachrichten
LONDON, March 6, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a systemic literature review and meta-analysis1 of its VISIONAIRE Pati…
Smith+Nephew''s VISIONAIRE Patient-Specific Instrumentation shown to improve outcome measures for total knee arthroplasty compared with conventional instrumentation 2023/03/06 13:00:00 PR Newswire
LONDON, March 6, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a systemic literature review and meta-analysis1 of its VISIONAIRE Patient-Specific Instrumentation (PSI) showing that its use leads to improvements in alignment…
Laparoscopic Devices Market Size And Forecast - 2022 to 2030 | DEAM, ConMed Corporation, Medtronic Plc, Smith & Nephew Plc, Richard Wolf GmbH 2023/02/24 12:40:59 OpenPR
Newark, New Castle, USA: Growth Plus Reports recently introduced a new title on Laparoscopic Devices Market 2022 and forecast 2030 from its database. The Laparoscopic Devices report provides a study with an in-depth overview, describing the product/industry scope and elaborates